Company overview：Gluetacs Therapeutics is the first biopharmaceutical company incubated by the ShanghaiTech University, focusing on addressing unmet medical needs in oncology and immunotherapy by developing oral protein degrader for major indications. The company has advanced its programs to Phase II clinical trials.

Differentiated dual-platform technology：Gluetacs Therapeutics is one of the few companies globally and the only one in China with intellectual property (IP)-protected dual platforms for molecular glues (Glue) and bifunctional degraders (GLUETAC). The company boasts an IP-protected molecular glue library of over 6,000 compounds (with more than 20 novel drug targets/first-in-class discoveries) and a bifunctional degrader library of over 6,000 compounds (covering 30 drug targets). Gluetacs has independently established an AI-powered virtual screening platform, in vitro efficacy screening platform, pharmacokinetics platform, proteomics platform, in vivo efficacy platform, clinical translation platform, and medical operations and registration platform, achieving a comprehensive end-to-end drug R&D system.

Indication Portfolio：Since its official operation in March 2021, Gluetacs Therapeutics has expanded its indication development from pipelines targeting hematologic malignancies with the first and second highest global incidence rates to those addressing solid tumors among the top ten globally, and further advanced to the development of autoimmune disease pipelines. (GT919: Multiple Myeloma; GT929: Non-Hodgkin’s Lymphoma; GT818: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, etc.; GT969: Inflammatory Bowel Disease, Arthritis, Psoriasis, Gout, etc.).

Corporate Vision：The R&D team at Gluetacs Therapeutics maintains a strong sense of purpose and passion, rooted in Lingang, Shanghai. Driven by unmet medical needs, the company has established a series of differentiated product pipelines. Guided by the development philosophy of “Being Innovative, Pioneering, and Benefiting Patients,” Gluetacs Therapeutics is committed to bringing value to patients and contributing to society.